Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 2,513 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Neoplasms
Interventions: Nilotinib and Paclitaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Daily ingestion of whole grain barley and oats; Other
Lead sponsor: United States Department of Agriculture (USDA); Federal
Eligibility: 25 Years to 70 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Beltsville, Maryland

Conditions: HIV, AIDS
Interventions: Video or In-Person Presentation; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Breast Cancer
Interventions: Placebo, Lidocaine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Progressive Multiple Sclerosis
Interventions: G-EO System (Reha Technology AG: Olten, Switzerland), Conventional Physical Therapy; Device · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Spinal Cord Injury
Interventions: Manual and mechanical assisted cough, Incentive spirometry; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Neurofibromatosis Type 1, Brain Tumor, Glioma
Interventions: Magnetic Resonance Imaging, Magnetic Resonance Fingerprinting; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Up to 35 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 12
States / cities: Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more

Conditions: PCOS
Interventions: DEXA, Magnetic Resonance (MR) Assessment of the Abdomen, MR assessment of Whole Body Fat, Adipose tissue biopsy, Oral glucose tolerance test; Other · Procedure
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Covid19, Vaccine Refusal, Vaccine Hesitancy
Interventions: COVID-19 Vaccine Education at the Point of COVID-19 Testing; Behavioral
Lead sponsor: Xavier University of Louisiana.; Other
Eligibility: 18 Years to 99 Years
Enrollment: 377 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Osteoarthritis, Knee
Interventions: Performance Clinical Outcome Test; Other
Lead sponsor: Canary Medical; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Frisco, Colorado • South Bend, Indiana • Jackson, Mississippi + 3 more

Conditions: Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
Interventions: Deferoxamine, Deferasirox, HIDA; Drug · Radiation
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercapnia
Interventions: standard of care for phase one anesthesia care, Quick Emergence Device; Other · Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer Study
Interventions: Fixed-Dose Combination (FDC) Tablet; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Hepatitis C, Chronic
Interventions: GS-5885, Tegobuvir, GS-9451, ribavirin tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 42
States / cities: Birmingham, Alabama • Dothan, Alabama • Anaheim, California + 34 more

Conditions: Obesity, Healthy
Interventions: PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan); Diagnostic Test · Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatitis C, Chronic
Interventions: HCV RNA screening; Other
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Albuquerque, New Mexico

Conditions: Type 1 Diabetes Mellitus
Interventions: Humalog, Novolog, BC222 insulin lispro, Bionic Pancreas; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder, Primary Hypersomnia, Bipolar Disorder, Narcolepsy, Primary Insomnia
Interventions: Acoustical slow wave induction; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Type 2 Diabetes Mellitus
Interventions: SAR342434, Humalog, insulin glargine HOE901; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 51
States / cities: Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more

Conditions: New Onset Atrial Fibrillation, Sepsis, Respiratory Failure
Interventions: Amiodarone in Parenteral Dosage Form, Amiodarone Pill, Direct Current Cardioversion (DCC), Rate-control therapy; Drug · Procedure
Lead sponsor: Our Lady of the Lake Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Influenza
Interventions: Rapid Influenza Testing with Xpert Flu; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 2,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Phoenix, Arizona • Sylmar, California • Baltimore, Maryland + 1 more

Conditions: Immunotherapy-related Pruritus
Interventions: TriCalm Hydrogel®, Triamcinolone acetonide 0.1% cream; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Generalized Anxiety Disorder, Bipolar Disorder
Interventions: Ziprasidone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

The Influence of Daily Intake of Whole Grain Barley or Oats on Biomarkers of Cardiovascular Disease

Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos

IRB-HSR# 13957: IV Lidocaine for Patients Undergoing Primary Breast Cancer Surgery:

G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis

Preventing Pneumonia and Other Respiratory Problems in Persons With Spinal Cord Injury

Feasibility and Clinically Application of Magnetic Resonance Fingerprinting

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Transcriptional and Epigenetic Program of PCOS Women

COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana

A Study of the Construct Validity of Community Walking Speed Data Collected Remotely With the Canary canturioTM te Tibial Extension

Pilot Study for Patients With Poor Response to Deferasirox

Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Sympathetic Activation in Obesity

Rapid HCV RNA Testing and LInkage to Care

Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

Neurophysiologic Correlates of Hypersomnia

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Rapid Atrial Fibrillation Treatment Strategy

Influenza Diagnosis, Treatment and Surveillance With Xpert Flu

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder